Klacid I.V. (Clarithromycin)

Clarithromycin exerts its antibacterial effect by binding to the 50S ribosomal subunit of susceptible bacteria. This binding blocks the translocation step of protein synthesis, preventing the formation of essential proteins and halting bacterial growth. The result is a bacteriostatic effect at standard concentrations and a bactericidal effect when higher drug levels are achieved.

The specific dose of Klacid I.V. is determined by the prescribing clinician based on the type and severity of the infection, the patient’s renal and hepatic function, and any relevant drug‑interaction considerations. Dosage regimens are individualized and should follow the guidance provided in the product’s prescribing information.

Clarithromycin is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Clarithromycin can be excreted in breast milk, so caution is advised for breastfeeding mothers.

To order Klacid I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Klacid I.V. (clarithromycin) offers a broader spectrum against certain Gram‑positive and atypical organisms compared with older macrolides such as erythromycin. Its intravenous formulation allows rapid achievement of therapeutic plasma concentrations, which can be advantageous in severe infections or when oral administration is not feasible. Resistance patterns and drug‑interaction profiles also differ, so selection should be based on susceptibility data and patient factors.

Klacid I.V. should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold‑chain ensures drug stability and potency throughout distribution and storage.

Klacid I.V. is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescribing information and the patient’s clinical condition. Compatibility with compatible IV fluids and appropriate aseptic technique should be observed during preparation and administration.

Serious risks include severe allergic reactions such as anaphylaxis, QT interval prolongation that can lead to life‑threatening arrhythmias, hepatic dysfunction including hepatitis, and Clostridioides difficile‑associated colitis. Patients should be monitored for signs of these events, and immediate medical attention is required if they occur.

Klacid I.V. should be avoided in patients with a known hypersensitivity to clarithromycin, other macrolides, or any component of the formulation. Caution is also advised for individuals with significant hepatic impairment, uncontrolled arrhythmias, or those taking medications that strongly prolong the QT interval. Clinical judgment is required to assess suitability.